newsfilter
← Latest News
Business Wire·

Clovis Oncology and ITM Announce Lutetium-177 Clinical Supply Agreement

ITM to supply its medical radioisotope, no-carrier-added Lutetium-177, for the clinical development of Clovis Oncology's Targeted Radionuclide Therapy candidate FAP-2286 Clovis Oncology, Inc. (NASDAQ:CLVS) and ITM Isotope Technologies Munic